SCHEMBL1285213

SCHEMBL1285213

Cc1cc(Br)cc([N+](=O)[O-])c1CN

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
ALDH1A1 P00352 5/20 0.40
CYP3A4 P08684 4/20 0.40
TSHR P16473 4/20 0.40
RECQL P46063 1/20 0.40
ERN1 O75460 1/20 0.39
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
S100A4 P26447 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
HSD17B10 Q99714 1/20 0.36
FBP1 P09467 1/20 0.35
GPR35 Q9HC97 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31184815 0.83 CYP1A2 (0.43) CYP1A2ALDH1A1CYP3A4TSHRRECQL
SCHEMBL31184560 0.83 CYP1A2 (0.43) CYP1A2ALDH1A1CYP3A4TSHRRECQL
SCHEMBL26685275 0.80 FBP1 (0.45) CYP1A2ALDH1A1TSHRERN1MAPT
SCHEMBL153660 0.78 ALDH1A1 (0.48) CYP1A2ALDH1A1CYP3A4TSHRRECQL
SCHEMBL117603 0.77 HTR1D (0.40) CYP1A2ALDH1A1CYP3A4TSHRHSD17B10
SCHEMBL13280627 0.76 CYP1A2 (0.66) CYP1A2ALDH1A1CYP3A4TSHRRECQL
SCHEMBL26684869 0.75 PDGFRB (0.51) CYP1A2ALDH1A1RECQLERN1MAPT
Hydrochloric Acid SCHEMBL26685644 0.75 HTR1D (0.39) CYP1A2ALDH1A1CYP3A4TSHRHSD17B10
SCHEMBL3346944 0.74 TSHR (0.44) CYP1A2ALDH1A1CYP3A4TSHRRECQL
SCHEMBL5201165 0.73 CYP1A2 (0.61) CYP1A2ALDH1A1CYP3A4TSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379529-B1 CGRP-ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-06-10 EP disclosed
US-8952014-B2 Pyrimidine derivatives which are CGRP—antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-20120088755-A1 Novel Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-12 US disclosed
EP-2379529-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-26 EP disclosed
WO-2010070022-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088755-A1 Novel Compounds SLC26A4, F12, SLCO1B3 CYP1A2 671/4885ALDH1A1 887/4885CYP3A4 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.